VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Tuesday, December 30, 2025
Stock Comparison
Altria Group, Inc. vs Novo Nordisk A/S
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Altria Group, Inc.
MO · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Altria Group, Inc.'s moat claims, evidence, and risks.
View MO analysisNovo Nordisk A/S
NOVOB · Nasdaq Copenhagen
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Novo Nordisk A/S's moat claims, evidence, and risks.
View NOVOB analysisComparison highlights
- Moat score gap: Altria Group, Inc. leads (88 / 100 vs 85 / 100 for Novo Nordisk A/S).
- Segment focus: Altria Group, Inc. has 3 segments (88.3% in Smokeable Products); Novo Nordisk A/S has 3 segments (71.1% in Diabetes care).
- Primary market structure: Oligopoly vs Oligopoly. Pricing power: Strong vs Moderate.
- Moat breadth: Altria Group, Inc. has 5 moat types across 3 domains; Novo Nordisk A/S has 5 across 3.
Primary market context
Altria Group, Inc.
Smokeable Products
U.S. cigarettes and machine-made cigars
United States
Wholesalers/distributors and large retail organizations (serving adult tobacco consumers 21+)
Manufacturer and brand owner
88.3%
Novo Nordisk A/S
Diabetes care
Diabetes pharmaceuticals (GLP-1 for type 2 diabetes, insulin, and related therapies)
Global
Payers/providers and patients (via wholesalers/pharmacies/hospitals)
Originator pharma (R&D, regulatory, manufacturing, commercialization)
71.1%
Side-by-side metrics
Moat coverage
Shared moat types
Altria Group, Inc. strengths
Novo Nordisk A/S strengths
Segment mix
Altria Group, Inc. segments
Full profile >Smokeable Products
Oligopoly
Oral Tobacco Products
Oligopoly
E-Vapor and New Products (NJOY, Horizon, R&D)
Competitive
Novo Nordisk A/S segments
Full profile >Diabetes care
Oligopoly
Obesity care
Duopoly
Rare disease
Oligopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.